Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

45.28 +0.16 (+0.37%)

Streaming Delayed Price Updated: 2:59 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	1,075,135
Open	45.00
Bid (Size)	45.28 (300)
Ask (Size)	45.30 (300)
Prev. Close	45.12
Today's Range	44.97 - 45.68
52wk Range	29.66 - 46.14
Shares Outstanding	388,132,400
Dividend Yield	1.94%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

3 Healthcare Stocks Walking a Fine Line

February 18, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

Via StockStory

5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call

February 18, 2026

Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key...

Via StockStory

Performance

YTD	+16.5%	+16.5%
1 Month	+12.1%	+12.1%
3 Month	+13.9%	+13.9%
6 Month	+25.8%	+25.8%
1 Year	+34.0%	+34.0%

More News

Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗

February 14, 2026

Via The Motley Fool

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗

February 11, 2026

Via Chartmill

Why Is TEVA Stock Rising Pre-Market Today? ↗

January 12, 2026

Via Stocktwits

Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗

February 11, 2026

Via The Motley Fool

Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings

February 11, 2026

Via StockStory

Royalty Pharma Reports Q4 and Full Year 2025 Results

February 11, 2026

From Royalty Pharma plc

Via GlobeNewswire

What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings

February 09, 2026

Via StockStory

3 Mid-Cap Stocks We Keep Off Our Radar

February 05, 2026

Via StockStory

3 Profitable Stocks with Open Questions

January 20, 2026

Via StockStory

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

January 20, 2026

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Royalty Pharma plc

Via GlobeNewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

January 11, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Royalty Pharma Announces Dividend Increase

January 09, 2026

From Royalty Pharma plc

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)

January 07, 2026

Via StockStory

3 Overrated Stocks We Steer Clear Of

December 31, 2025

Via StockStory

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

December 29, 2025

From Royalty Pharma plc

Via GlobeNewswire

3 Healthcare Stocks We’re Skeptical Of

December 16, 2025

Via StockStory

Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

December 16, 2025

From Royalty Pharma plc

Via GlobeNewswire

What's going on in today's after hours session ↗

December 08, 2025

Via Chartmill

Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shows Strong Technical Setup for a Breakout ↗

December 06, 2025

Via Chartmill

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Royalty Pharma plc

Via GlobeNewswire

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Denali Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Royalty Pharma plc - Class A Ordinary Shares publicly traded?

Yes, Royalty Pharma plc - Class A Ordinary Shares is publicly traded.

What exchange does Royalty Pharma plc - Class A Ordinary Shares trade on?

Royalty Pharma plc - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Royalty Pharma plc - Class A Ordinary Shares?

The ticker symbol for Royalty Pharma plc - Class A Ordinary Shares is RPRX on the Nasdaq Stock Market

What is the current price of Royalty Pharma plc - Class A Ordinary Shares?

The current price of Royalty Pharma plc - Class A Ordinary Shares is 45.28

When was Royalty Pharma plc - Class A Ordinary Shares last traded?

The last trade of Royalty Pharma plc - Class A Ordinary Shares was at 02/23/26 02:59 PM ET

What is the market capitalization of Royalty Pharma plc - Class A Ordinary Shares?

The market capitalization of Royalty Pharma plc - Class A Ordinary Shares is 17.58B

How many shares of Royalty Pharma plc - Class A Ordinary Shares are outstanding?

Royalty Pharma plc - Class A Ordinary Shares has 18B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.